Author: Dr. Michael Lichtenberg

Institution: Vascular Center Arnsberg, Germany

Summary

This presentation explores the application of mechanical thrombectomy in the treatment of deep vein thrombosis (DVT), with a focus on the ClotTriever catheter system and its clinical use in acute and subacute iliac-femoral DVT patients. The study highlights the system’s safety and efficacy in reducing residual thrombus and preventing post-thrombotic syndrome (PTS), with no significant device-related complications reported.

Key Points

•Current Challenges in DVT Treatment:

• Residual thrombus remains a significant challenge, with up to 50% of patients experiencing it after anticoagulation or catheter-directed thrombolysis (CDT) . 

• This issue is closely linked to the development of PTS, increasing the risk of long-term complications.

• PTS can significantly affect quality of life, with patients experiencing outcomes comparable to those of congestive heart failure or cancer patients.

•ClotTriever System Advantages:

•The ClotTriever catheter system mechanically removes thrombus from iliac-femoral veins, avoiding the bleeding risks associated with traditional CDT. Initial clinical data shows a 92% vessel patency rate within six months (PPT 11).

•In the CLOUT registry study, involving 500 patients treated with ClotTriever, there were no major adverse events (MAE) reported within 30 days, and all patients achieved successful treatment outcomes without device-related complications (PPT 12).

Conclusion

1. The ClotTriever mechanical thrombectomy system offers a safe and effective treatment for acute and subacute iliac-femoral DVT patients, significantly reducing residual thrombus and lowering the risk of PTS.

2. Compared to traditional anticoagulation and CDT, mechanical thrombectomy has clear advantages in shortening treatment times, reducing bleeding risks, and improving technical success rates.

3. As more clinical data becomes available, mechanical thrombectomy is poised to become a primary method in DVT treatment, improving long-term outcomes for patients.

Contact Us

For submissions, please contact us at: endovascluar@simtomax.cn

Thank you for your attention, and let’s continue to safeguard health together!

More international information available at:

•www.vascularknight.com

•Facebook: Vasco Knight

•Instagram: knight_vasco